Olpasiran
amgen
[]
oceana dose trial presented at #aha22 by . #olpasiran reduces #lpa by more than 95% in patients with ascvd. 
Johns Hopkins Medicine. Associate Professor, Cardiology. Co-Editor in Chief @AJPCardio. #WomenHeartHealth #CardioObstetrics #cvPrev #echofirst She/her #BeKind